OLEMA PHARMACEUTICALS, INC. Gain (Loss) on Disposition of Assets
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Gain (Loss) on Disposition of Assets of -$9.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-03-16
- OLEMA PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2023-12-31 was $0.00.
- OLEMA PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2023-09-30 was -$103.00K.
- OLEMA PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2024 was -$9.00K.
- OLEMA PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2023 was -$111.00K.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$9.00K 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$103.00K derived: sum of 2 quarters · filed 2025-03-18 | -$111.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | -$103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$111.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$8.00K 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |